Related Experiment Video
Updated: Jun 29, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.2K
Italian Society of Interventional Cardiology (GISE) and Italian Society of Arterial Hypertension (SIIA) Position
Eugenio Stabile1, Maria L Muiesan2, Flavio L Ribichini3
1Division of Cardiology, Cardiovascular Department, Azienda Ospedaliera Regionale "San Carlo", Potenza, Italy.
Minerva Cardiology and Angiology
|March 27, 2024
Summary
Renal denervation (RDN) offers a safe and effective treatment for resistant hypertension, comparable to medications. A multidisciplinary approach is key for patient selection and management to optimize outcomes.
Area of Science:
- Cardiology
- Nephrology
- Vascular Medicine
Background:
- Resistant hypertension poses a significant clinical challenge.
- Renal denervation (RDN) has emerged as a potential therapeutic option.
- The role of RDN in managing difficult-to-treat hypertension requires further elucidation.
Purpose of the Study:
- To evaluate the efficacy and safety of renal denervation (RDN) for resistant hypertension.
- To compare the blood pressure-lowering effects of RDN with antihypertensive medications.
- To highlight the importance of a multidisciplinary team in RDN procedures.
Main Methods:
- Systematic review of clinical trials evaluating RDN.
- Meta-analysis of blood pressure reduction post-RDN.
- Analysis of patient selection and post-procedural management protocols.
Main Results:
- Renal denervation (RDN) demonstrates significant blood pressure reduction in patients with resistant hypertension.
- The efficacy of RDN is comparable to established antihypertensive drug therapies.
- A comprehensive, multidisciplinary approach is crucial for successful RDN outcomes.
Conclusions:
- Renal denervation (RDN) is a valuable addition to the treatment armamentarium for resistant hypertension.
- RDN can be considered alongside lifestyle modifications and pharmacotherapy.
- Further research is warranted to identify predictors of response and assess long-term clinical outcomes.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:25Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159